Skip to main content

Table 1 Baseline characteristics of the DCH study participants by selected demographic and established BC risk factors

From: Alcohol-related breast cancer in postmenopausal women – effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial

Variable

Cases

Controls

IRRa (95 % CI)

n (%)

Median (5–95 %)

n (%)

Median (5–95 %)

 

Women

687 (100)

 

687 (100)

  

Age at inclusion, years

 

57 (51–64)

 

57 (51–64)

 

School education

     

 Short

198 (29)

 

257 (37)

 

1.0 (ref.)

 Medium

344 (50)

 

316 (46)

 

1.39 (1.07–1.79)

 Long

145 (21)

 

114 (17)

 

1.59 (1.13–2.24)

Body mass index, kg/m2

 

25 (20–34)

 

25 (20–34)

1.01 (0.96–1.07)b

Nulliparous

102 (15)

 

78 (11)

 

1.02 (0.64–1.60)c

Number of births

 

2 (1–4)

 

2 (1–4)

0.92 (0.79–1.06)

Age at first birth, years

 

23 (18–31)

 

23 (18–32)

1.07 (0.91–1.25)d

Use of HRT, yearse

 

6 (0.5–19)

 

5 (0.5–20)

1.00 (0.87–1.15)f

Abstainers

15 (2)

 

22 (3)

 

0.80 (0.40–1.61)g

Alcohol intake, g/day

 

11 (1–43)

 

9 (1–40)

1.12 (1.04–1.21)h

NSAID usei

286 (42)

 

239 (35)

 

1.33 (1.07–1.66)

  1. Values are expressed as medians (5th and 95th percentiles) or as fractions (%)
  2. aThe risk estimates for breast cancer are mutually adjusted
  3. bThe risk is estimated per additional 2 kg/m2
  4. cThe risk is estimated for nulliparous versus one birth at age 35
  5. dThe risk is estimated per additional 5 years
  6. eAmong ever users of HRT
  7. fThe risk is estimated per additional 5-year of HRT use
  8. gThe risk for abstainers compared to the increment of 10 g alcohol per day
  9. hAmong drinkers, risk estimate is estimated for the increment of 10 g alcohol per day
  10. i NSAID use is defined as ≥ 2 pills per month during one year